Incidence and Significance of Cardiac Troponin I Release in Severe Trauma Patients

Alain Edouard(Générale de Santé), Dan Benhamou(Générale de Santé), Marie-Louise Felten(European Society of Anaesthesiology), Claudine Cosson(Générale de Santé), Jean‐Louis Hébert(Sorbonne Université), Laurent Martin

Anesthesiology

November 24, 2004

10.1097/00000542-200412000-00004

Cited by 82

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

|Allergy|2018|1.4k

The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

|Allergy|2014|1.2k

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

|Allergy|2004|1.1k

Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma

|Clinical & Experimental Allergy|2004|520

New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure

|CHEST Journal|2004|497